2,2-Dimethyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)propan-1-amine → 5-cyclopropyl-N-[2,2-dimethyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)propyl]-4-(2,2,2-trifluoroethoxy)pyridine-2-carboxamide
反応式
[CH:1]1([C:4]2[C:5]([O:13][CH2:14][C:15]([F:18])([F:17])[F:16])=[CH:6][C:7]([C:10]([OH:12])=O)=[N:8][CH:9]=2)[CH2:3][CH2:2]1.[CH3:19][C:20]([CH3:30])([CH3:29])[CH:21]([C:23]1[O:24][C:25]([CH3:28])=[N:26][N:27]=1)[NH2:22]>>[CH:1]1([C:4]2[C:5]([O:13][CH2:14][C:15]([F:18])([F:17])[F:16])=[CH:6][C:7]([C:10]([NH:22][CH:21]([C:23]3[O:24][C:25]([CH3:28])=[N:26][N:27]=3)[C:20]([CH3:19])([CH3:29])[CH3:30])=[O:12])=[N:8][CH:9]=2)[CH2:2][CH2:3]1参加物
3
実験手順
The title compound was synthesized in analogy to Example 112e, using 5-Cyclopropyl-4-(2,2,2-trifluoro-ethoxy)-pyridine-2-carboxylic acid (Example 48c) and 2,2-dimethyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)propan-1-amine (example 174b) as starting materials and isolated (128 mg, 81%); MS (ESI, m/z): 413.6 (M+H+).
後処理
- customisolated (128 mg, 81%)